Mucinex Fast-Max Advertising Claim Exceeds Indications In NAD Review
This article was originally published in The Pink Sheet
Executive Summary
Review was second in two years by the Council of Better Business Bureaus' National Advertising Division of a challenge to Reckitt Benckiser ad claims for its Mucinex cough/cold line made by Procter & Gamble, which markets competing products including Vicks NyQuil and DayQuil brands.
You may also be interested in...
Unreliable Survey Doesn't Sink Mucinex Fast-Max 'All In One' Claim In NAD Review
RB didn't get help from consumer perception survey to support argument that "All In One" label statement is not claim the product treats all cold and flu symptoms. Council of Better Business Bureaus' division dismisses survey as faulty but approves RB's argument. NAD attorneys conclude 15- and 6-second TV and video "superhero 'movie trailer'” ads did not include "a sufficiently proximate and prominent list of symptoms" to counter "distracting features."
Mucinex On Target In DayQuil Comparison Despite Disparate Formulations
RB’s ad comparing Mucinex Fast-Max Liquid Gels to Procter & Gamble’s DayQuil LiquiCaps is not misleading because, even though they have different formulations, the products compared were clearly identified, the National Advertising Division says.
Industry News Roundup
Acetaminophen skin reacting warning in draft guidance; supplement ingredient testing exemption option continues; FTC breaks Habitrol from GSK/Novartis JV; NARB stops clock on Mucinex 8-minute claim; kick start for ClickStick; NVC drinks up Blu-Dot; drug claims, GMP problems for Avena Botanicals; Ugam beefs up MusclePharm price monitoring; Nutraceutical International growth trims income; SDC Nutrition on global mission; and Naturally Splendid acquires Full Spectrum technology.